KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia

- H3K27 and selected H3K9 demethylases show upregulated expression in human AML.
- Elevated KDM6 expression correlates with reduced global H3K27Me3 in AML.
- KDM6 inhibition with GSKJ4 reduces AML cell survival.
- Combination with KDM4 inhibition increases efficacy of GSKJ4.